Kerstin Port

Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial

Heiner Wedemeyer, Cihan Yurdaydın, Svenja Hardtke et al. · The Lancet Infectious Diseases · 2019 · 185 citations

Hepatitis D, Hepatology, Viral Hepatitis +8

Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial

Heiner Wedemeyer, Katrin Schöneweis, Pavel Bogomolov et al. · The Lancet Infectious Diseases · 2022 · 138 citations

Hepatology, Viral Hepatitis, Pharmacology +9

Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B

Christoph Höner zu Siederdissen, Franziska Rinker, Benjamin Maasoumy et al. · The Journal of Infectious Diseases · 2016 · 136 citations · Full text

Hbsag Loss, Immunology, Hepatitis B +19

Improvement of liver function parameters in advanced <scp>HCV</scp> ‐associated liver cirrhosis by <scp>IFN</scp> ‐free antiviral therapies

Katja Deterding, Christoph Höner zu Siederdissen, Kerstin Port et al. · Alimentary Pharmacology & Therapeutics · 2015 · 120 citations · Full text

Compromised Function of Natural Killer Cells in Acute and Chronic Viral Hepatitis

Sebastian Lunemann, David F. G. Malone, Julia Hengst et al. · The Journal of Infectious Diseases · 2013 · 116 citations